Immutep has announced topline results from the trial evaluating its eftilagimod alfa in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent and metastatic head and neck squamous cell carcinoma. …
Australian company reports topline results from clinical trial involving MSD's Keytruda
June 28, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The 'Week in Review' Podcast - 28 June
June 28, 2024 - - Podcast -
Parliament backs changes included in the new Community Pharmacy Agreement
June 28, 2024 - - Latest News -
Australian company reports topline results from clinical trial involving MSD's Keytruda
June 28, 2024 - - Latest News -
TrailblAZers speaks with a leader about their current public campaign
June 27, 2024 - - Podcast -
PhRMA says new analysis shows how new pricing power will raise costs for millions
June 27, 2024 - - Latest News -
Pharmacy groups lament parliamentary support for more accessible vapes
June 27, 2024 - - Latest News -
Makers will be delighted these products will be more accessible from pharmacies
June 27, 2024 - - Latest News